These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38102573)

  • 1. Integrative analysis of purine metabolites and gut microbiota in patients with neuromyelitis optica spectrum disorders after mycophenolate mofetil treatment.
    Li G; Ma X; Xia L; Wei R; Wang X; Li C; Wang Y; He L; Ren H; Sun J; Qiu W
    BMC Neurol; 2023 Dec; 23(1):444. PubMed ID: 38102573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of gastrointestinal toxicity in neuromyelitis optica spectrum disorder patients treated with mycophenolate mofetil: insights from a mouse model and human study.
    Li G; Xia L-J; Shu Y-Q; Wan L; Huang Q; Ma X-Y; Zhang H-Y; Zheng Z-J; Wang X-R; Zhou S-Y; Gao A; Ren H; Lian X-L; Xu D; Tang S-Q; Liao X-P; Qiu W; Sun J
    Microbiol Spectr; 2024 Aug; 12(8):e0430723. PubMed ID: 38916339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
    Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
    Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY
    J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study.
    Jiao Y; Cui L; Zhang W; Zhang C; Zhang Y; Zhang X; Jiao J
    BMC Neurol; 2018 Apr; 18(1):47. PubMed ID: 29688841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
    Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
    Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients.
    Pathomrattanapiban C; Tisavipat N; Jitprapaikulsan J; Prayoonwiwat N; Rattanathamsakul N; Siritho S
    Mult Scler Relat Disord; 2022 Jul; 63():103882. PubMed ID: 35598463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of azathioprine and mycophenolate mofetil response in patients with neuromyelitis optica spectrum disorder: A cohort study.
    San Martin DL; Fukuda TG; Nascimento TS; Silva MB; Filho MBP; Forcadela M; Rocchi C; Gibbons E; Hamid S; Huda S; Oliveira-Filho J
    Mult Scler Relat Disord; 2024 Mar; 83():105452. PubMed ID: 38277981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Ma J; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 Oct; 55():103181. PubMed ID: 34365314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
    Shi Z; Du Q; Chen H; Zhang Y; Qiu Y; Zhao Z; Wang J; Yan C; Zhang Q; Yang M; Zhou H
    J Neurol; 2020 Apr; 267(4):913-924. PubMed ID: 31776721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
    Huh SY; Kim SH; Hyun JW; Joung AR; Park MS; Kim BJ; Kim HJ
    JAMA Neurol; 2014 Nov; 71(11):1372-8. PubMed ID: 25199960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
    Huang W; Wang L; Xia J; Li W; Wang M; Yu J; Li Q; Wang B; Pan J; Du L; Ma J; Tan H; Chang X; Lu C; Zhao C; Lu J; Zhou L; ZhangBao J; Quan C;
    Eur J Neurol; 2022 Aug; 29(8):2343-2354. PubMed ID: 35398950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
    Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H
    Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
    Cao S; Yu H; Tian J; Li Y; Shen Y; Ji X; Wang X; Zhou X; Gu Y; Zhu F; Duan X; Xiao X; Fang Q; Chen X; Xue Q
    J Neurol Sci; 2021 Oct; 429():117616. PubMed ID: 34450520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
    Dresser L; Chaar WA; Reder AT; Abuaf AF; Cipriani VP; Javed A
    Mult Scler Relat Disord; 2023 Jun; 74():104718. PubMed ID: 37086634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.
    Kim SH; Hyun JW; Joung A; Park EY; Joo J; Kim HJ
    Mult Scler; 2017 Dec; 23(14):1902-1908. PubMed ID: 28080220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Espiritu AI; Pasco PMD
    Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China.
    Huang Q; Wang J; Zhou Y; Yang H; Wang Z; Yan Z; Long Y; Yin J; Feng H; Li C; Lu Z; Hu X; Qiu W
    Front Immunol; 2018; 9():2066. PubMed ID: 30258442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.